Harnessing oncolytic virus-mediated immunity / / topic editors: Philippe Fournier and Volker Schirrmacher.
Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-onco...
Saved in:
| TeilnehmendeR: | |
|---|---|
| Place / Publishing House: | Switzerland : : Frontiers Media SA,, 2015 |
| Year of Publication: | 2015 |
| Language: | English |
| Series: | Frontiers Research Topics
|
| Physical Description: | 1 online resource (110 pages) :; illustrations; digital, PDF file(s). |
| Notes: | Bibliographic Level Mode of Issuance: Monograph |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic addresses various strategies how to optimize OVs anti-tumor activity. |
|---|---|
| Bibliography: | Includes bibliographical references. |
| ISBN: | 9782889193080 (ebook) |
| Hierarchical level: | Monograph |
| Statement of Responsibility: | topic editors: Philippe Fournier and Volker Schirrmacher. |